Underrepresentation of Elderly People in Randomised Controlled Trials. The Example of Trials of 4 Widely Prescribed Drugs

Abstract

BackgroundWe aimed to determine the representation of elderly people in published reports of randomized controlled trials (RCTs). We focused on trials of 4 medications—pioglitazone, rosuvastatin, risedronate, and valsartan—frequently used by elderly patients with chronic medical conditions.Methods and FindingsWe selected all reports of RCTs indexed in PubMed from 1966 to April 2008 evaluating one of the 4 medications of interest. Estimates of the community-based “on-treatment” population were from a national health insurance database (SNIIR-AM) covering approximately 86% of the population in France. From this database, we evaluated data claims from January 2006 to December 2007 for 1,958,716 patients who received one of the medications of interest for more than 6 months. Of the 155 RCT reports selected, only 3 studies were exclusively of elderly patients (2 assessing valsartan; 1 risedronate). In only 4 of 37 reports (10.8%) for pioglitazone, 4 of 22 (18.2%) for risedronate, 3 of 29 (10.3%) for rosuvastatine and 9 of 67 (13.4%) for valsartan, the proportion of patients aged 65 or older was within or above that treated in clinical practice. In 62.2% of the reports for pioglitazone, 40.9% for risedronate, 37.9% for rosuvastatine, and 70.2% for valsartan, the proportion of patients aged 65 or older was lower than half that in the treated population. The representation of elderly people did not differ by publication date or sample size.ConclusionsElderly patients are poorly represented in RCTs of drugs they are likely to receive.

Routinely collected data and comparative effectiveness evidence: promises and limitations

“…Certain populations are frequently underrepresented in RCTs, including children, women, older adults or patients with comorbidities and polypharmacy. [6][7][8][9][10] Drug-drug interactions or adverse effects occurring in routine care may be overlooked. Cost considerations prohibit large studies that would be informative for subgroup-specific effects.…”

Treatment Characteristics of Acute Coronary Syndrome in Elderly Patients: Practice of N.I. Pirogov City Clinical Hospital №1

“…Очевидная причина того, почему в значительном проценте случаев у пациентов с ОКС в та-ких регистрах, как GRACE [17] и CRUSADE [1] реко-мендации по назначению антиагрегантной терапии не выполнялись -наличие у пациентов риска кровотече-ний. Неоднократно отмечалось, что в РКИ, лежащих в основе формирования рекомендаций, наблюдалась не только меньшая, чем в реальной практике доля пожи-лых пациентов и женщин, но и большинство комор-бидных состояний являлись критерием исключения [18,19]. Это делает правомочным вопрос, который ста-вили некоторые авторы: о возможности безоговороч-ного выполнения рекомендаций в реальной клиниче-ской практике [5].…”

Coronary Reperfusion in Senile Patients With Acute St Elevation Myocardial Infarction

“…Соответствующие рекомендации по выбору метода реперфузии основаны на результатах многочисленных рандомизированных исследований и метаанализах последних [9]. Но в исследования, на которых осно-ваны рекомендации, больные старшей возрастной группы включались, как правило, в значительно мень-шей пропорции по сравнению с их долей в общей популяции больных [10,11]. В метаанализ Dodd KS, et al было включено 80 исследований по острому коро-нарному синдрому [12].…”